Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Although osteoporosis can be effectively treated with inhibitors of bone turnover or with bone forming agents, few data are available about an optimum approach. Here, Papapoulos and Makras discuss whether choices can be made based on the available evidence, addressing issues such as selection of patients for treatment, efficacy in lowering fracture risk and monotherapy versus combined therapy.
Treatment of thyroid cancer has not changed substantially for many years; however, few effective therapies are available for tumors that are metastatic or unable to take up radioiodine. The author of this Viewpoint, therefore, argues for the need to increase individual treatment efficacy through the introduction of novel targeted therapies.
Some studies have reported reduced secretion of glucagon-like peptide-1 (GLP-1) in patients with type 2 diabetes mellitus; however, other studies have failed to find such an association. The evidence for, and against, reduced GLP-1 secretion in the etiology of type 2 diabetes mellitus is debated by the authors of this Viewpoint.
